Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX®1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study

Vaccine

Volumn 27, Issue 33, 2009, Pages 4483-4489

  Kaltenbock A ^a   Dubischar Kastner, K ^a   Eder, G ^b   Jilg, W ^c   Klade, C ^a   Kollaritsch, H ^d   Paulke Korinek, M ^d   von Sonnenburg, F ^e   Spruth, M ^a   Tauber, E ^a   Wiedermann, U ^d   Schuller, E ^a  

^a INTERCELL AG   (Austria)

^b Karl Landsteiner Institute of Epidemiology of Infectious Diseases and Vaccinology   (Austria)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

Concomitant vaccination; Hepatitis A; IC51; Interaction; Japanese encephalitis; Travel

Indexed keywords

HEPATITIS A VACCINE; JAPANESE ENCEPHALITIS VACCINE;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; EPIDEMIC ENCEPHALITIS; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SINGLE BLIND PROCEDURE; TRAVEL; VACCINATION;

ADULT; ENCEPHALITIS, JAPANESE; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; JAPANESE ENCEPHALITIS VACCINES; MALE; SINGLE-BLIND METHOD; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 67649365435     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.034     Document Type: Article

References (31)

1. Vaughn D.W., and Hoke C.H. The epidemiology of Japanese encephalitis: prospects for prevention. Epidem Rev 14 (1992) 197-221
2. Sanchez J.L., Hoke C.H., McCowan J., DeFraites R.F., Takafuji E.T., Diniega B.M., et al. Further experience with Japanese encephalitis vaccine. Lancet 335 (1990) 972-973
3. Anderson M.M., and Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet 337 (1991) 1044
4. Ruff T.A., Eisen D., Fuller A., and Kass R. Adverse reactions to Japanese encephalitis vaccine. Lancet 338 (1991) 881-882
5. Berg S.W., Mitchell B.S., Hanson R.K., Olafson R.P., Wiliams R.P., Tueller J.E., et al. Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine. Clin Infect Dis 24 (1997) 265-266
6. Plesner A.M., and Ronne T. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine 15 (1997) 1239-1243
7. World Health Organization. Wkly Epidemiol Rec 80 (2005) 241-248. http://www.who.int/wer/2005/wer8028.pdf Available at: http://www.who.int/wer/2005/wer8028.pdf
8. Tauber E., Kollaritsch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 370 9602 (2007) 1847-1853
9. Centers of Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization. Recommendations and Reports 2006; 55(RR07): 1-23. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5507a1.htm.
10. Rendi-Wagner P., Korinek M., Winkler B., Kundi M., Kollaritsch H., and Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine 25 5 (2007) 927-931
11. van Damme Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 5 (2007) 79-84
12. Sukhavachana P., Yuill T.M., and Russell P.K. Assay of arbovirus neutralizing antibody by micro methods. Trans R Soc Trop Med Hyg 63 4 (1969) 446-455
13. Hombach J., Solomon T., Kurane I., Jacobson J., and Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23 45 (2005) 5205-5211
14. Böhning D., and Sarol Jr. J. Estimating risk difference in multicenter studies under baseline-risk heterogeneity. Biometrics 56 1 (2000) 304-308
15. van Damme P., Mattheï C., Thoelen S., Meheus A., Safary A., and André F.E. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol 44 4 (1994) 435-441
16. Solomon T. Control of Japanese encephalitis-within our grasp?. N Engl J Med 355 (2006) 869-871
17. Plesner A.M. Allergic reactions to Japanese encephalitis vaccine. Immunol Allergy Clin N Am 23 (2003) 665-697
18. Caramello P., Canta F., Balbiano R., Lipani F., Ariaudo S., De Agostini M., et al. A case of imported JE acquired during short travel in Vietnam. Are current recommendations about vaccination broader?. J Travel Med 14 5 (2007) 346-348
19. Oya A., and Kurane I. Japanese encephalitis for a reference to international travelers. J Travel Med 14 4 (2007) 259-268
20. World Health Organization: International travel and health 2008. Situation as on 01. January 2008. Geneva: World Health Organization; 2008.
21. Chlíbek R., Smetana J., Sindelár R., Cecetková B., Prymula R., and Kohl I. Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age-impact of risk factors. Epidemiol Mikrobiol Imunol 56 3 (2007) 119-128 (Article in Czech)
22. Atabani S., Landucci G., Steward M.W., Whittle H., Tilles J.G., and Forthal D.N. Sex-associated differences in the antibody-dependent cellular cytotoxicity antibody response to measles vaccines. Clin Diagn Lab Immunol 7 1 (2000) 111-113
23. Weissman S., Feucht C., and Moore B.A. Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepat 13 2 (2006) 81-86
24. Ashur Y., Adler R., Rowe M., and Shouval D. Comparison of immunogenicity of two hepatitis A vaccines - VAQTA and HAVRIX - in young adults. Vaccine 17 18 (1999) 2290-2296
25. Braconier J.H., Wennerholm S., and Norrby S.R. Comparative immunogenicity and tolerance of Vaqta and Havrix. Vaccine 17 17 (1999) 2181-2184
26. Bryan J.P., Henry C.H., Hoffman A.G., South-Paul J.E., Smith J.A., Cruess D., et al. Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 19 7-8 (2000) 743-750
27. Bovier P.A., Farinelli T., and Loutan L. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. Vaccine 23 19 (2005) 2424-2429
28. HAVRIX™: product approval information. Summary for basis of approval. Available at: http://www.fda.gov/cber/sba/havrixS.pdf (accessed 07 May 2008).
29. Berger R., Just M., and Althaus B. Time course of hepatitis A antibody production after active, passive and active/passive immunisation: the results are highly dependent on the antibody. J Virol Methods 43 3 (1993) 287-297
30. Jilg W, Mayer J, Plötz K, Baier, B, Hottenträger B. Vergleich zweier Anti-HAV-Teste zur Messung spezifischer Antikörper nach Hepatitis-A-Impfung. In: Maass G, Stück B., editors. Abstract in: Virushepatitis A bis E Diagnose, Therapie, Prophylaxe; 1994.
31. Wiedmann M., Boehm S., Schumacher W., Swysen C., and Zauke M. Evaluation of three commercial assays for the detection of hepatitis a virus. Eur J Clin Microbiol Infect Dis 22 2 (2003) 129-130